A Cr2AlC MAX Phase-Based Electrochemical Probe for the Detection of Asciminib in Biological and Pharmaceutical Samples

Basit Öğe Kaydı
dc.authoridBouali, Wiem/0009-0004-5096-6804
dc.contributor.authorGenc, Asena Ayse
dc.contributor.authorBouali, Wiem
dc.contributor.authorErk, Nevin
dc.contributor.authorKaya, Gul
dc.contributor.authorOcakoglu, Kasim
dc.date.accessioned2025-03-17T12:27:40Z
dc.date.available2025-03-17T12:27:40Z
dc.date.issued2025
dc.departmentTarsus Üniversitesi
dc.description.abstractThe Cr2AlC MAX phase, a two-dimensional transition metal carbide, offers a compelling combination of properties ideal for electrochemical sensor fabrication. The exceptional electrical conductivity, high surface area, and inherent electrocatalytic activity of the catalyst enable the sensitive and selective detection of diverse analytes, including biomolecules of critical clinical relevance. This work presents the construction of a novel electrochemical sensor featuring a nanoscale Cr2AlC MAX phase-modified electrode, demonstrating its exceptional analytical performance in Asciminib detection, a crucial aspect of chronic myeloid leukemia (CML) treatment. The sensor exhibits a low limit of detection (0.212 mu M) and a low limit of quantification (0.698 mu M) and demonstrates excellent sensitivity toward Asciminib in the linear range of 1 mu M-10 mu M. Moreover, a rigorous tolerance limit has been established, allowing the sensor to tolerate the highest concentration of interfering substances with an error of less than +/- 5% in determining ASC current. Successful quantification of Asciminibin biological samples further validates the method's reliability for real-world applications. This novel electrochemical approach provides a rapid and cost-effective alternative to existing methods and contributes significantly to the nanomaterial-enabled advancement of CML management, ensuring precise Asciminib quantification at the nanoscale.
dc.description.sponsorshipScientific Research Projects Coordination Unit of Ankara University [TSA-2023-2738]
dc.description.sponsorshipThis work was supported by the Scientific Research Projects Coordination Unit of Ankara University with the project number TSA-2023-2738.
dc.identifier.doi10.1002/slct.202404450
dc.identifier.issn2365-6549
dc.identifier.issue2
dc.identifier.scopus2-s2.0-85215325630
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1002/slct.202404450
dc.identifier.urihttps://hdl.handle.net/20.500.13099/2386
dc.identifier.volume10
dc.identifier.wosWOS:001397363400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofChemistryselect
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250316
dc.subjectAnticancer drug
dc.subjectAsciminib
dc.subjectCr2AlC MAX phase
dc.subjectElectrochemical sensor
dc.subjectPharmaceutical analysis
dc.titleA Cr2AlC MAX Phase-Based Electrochemical Probe for the Detection of Asciminib in Biological and Pharmaceutical Samples
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu